Answers are grounded in this paper and cite their sources.
Retrospective review assesses bimekizumab outcomes in patients previously treated with IL-17 inhibitors, suggesting effective switching strategies.
To the Editor: Bimekizumab is the most recent interleukin-17 inhibitor (IL-17i) to receive approval for adult plaque psoriasis; unlike other IL-17i agents, it exclusively targets IL-17A/IL-17F. While biologic switching is common in routine clinical practice, limited information exists on switching from another IL-17i agent to bimekizumab.1,2 We conducted a real-world, multicenter, retrospective study of bimekizumab use in the setting of prior IL-17i exposure.
No takes yet. Share an insight, caveat, or question.
Sood et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: